Jonathan Siegal Sells Shares of Vericel Corporation

On June 26, 2026, Jonathan Siegal, the Principal Accounting Officer at Vericel Corporation, sold 2,732 shares of the company. This planned transaction was valued at approximately $122,666.80, with the shares sold at an average price of $44.90 each.

Insider Buying and Selling at Vericel Corporation

Jonathan Siegal's recent sale of 2,732 shares was part of a planned transaction. On the same day, Siegal also purchased 2,500 shares at $29.82, indicating active management of his holdings. Additionally, Vericel's Chief Medical Officer, Jonathan Mark Hopper, bought 5,000 shares at the same price, and Chief Legal Officer Sean Flynn made significant transactions, buying 15,000 shares at $16.25 and selling another 15,000 shares at $45.64, both of which were planned.

Other Institutional Activity in Vericel Corporation

BlackRock, Inc. increased its holdings in Vericel by 58,269 shares, bringing its total to over 7.76 million shares valued at approximately $249.81 million. Soleus Capital Management, L.P. significantly boosted its position by 1,785,079 shares, now holding about 2.55 million shares worth $82 million, marking a 233.6% increase. Vanguard Capital Management LLC opened a new position with 2,230,756 shares valued at around $71.76 million. Meanwhile, State Street Corp reduced its stake slightly by 11,792 shares, and William Blair Investment Management, LLC cut its position by 389,398 shares, a 17.5% decrease.

Vericel Corporation Stock Up 8.6%

Shares of Vericel Corporation (NasdaqGM:VCEL) traded near $44.49 on Wednesday. The company boasts a market capitalization of approximately $2.27 billion. Despite a high P/E ratio of 103.5, its forward P/E is more reasonable at 52.2, indicating expectations of future earnings growth. The stock has a 52-week range between $28.95 and $46.62, with a 50-day moving average of $36.28 and a 200-day moving average of $35.73. Vericel's financial position is strong, with a current ratio of 5.18 and a quick ratio of 4.62, though it carries a debt-to-equity ratio of 26.68.

Analysts Set New Price Targets

Truist Securities has maintained a 'buy' rating on Vericel, setting a price target of $42 as of April 15, 2026. HC Wainwright & Co. also maintains a 'buy' rating, with a higher target of $64. The consensus among seven analysts suggests a mean price target of $55.43, reflecting optimism about the company's future prospects.

About Vericel Corporation

Vericel Corporation is a biopharmaceutical company based in Burlington, Massachusetts. It specializes in cellular therapies and biologic products for the sports medicine and severe burn care markets in North America. The company markets products like MACI, Epicel, and NexoBrid, which are used for cartilage repair and burn treatment. Led by CEO Dominick C. Colangelo, Vericel employs nearly 400 people and continues to focus on innovative treatments in the healthcare sector.

Bottom Line

Jonathan Siegal's recent sale of Vericel shares is part of planned transactions, reflecting active insider management. Investors closely watch insider trades for insights into company sentiment. Vericel's stock remains a point of interest, especially given its market positioning and analyst optimism. As always, it's important to remember that insider activity is just one piece of the investment puzzle.